REMED Therapeutics is a subsidiary of Bessor Pharma based on technologies discovered in the laboratory of Dr. Gary Désir, Chair of Medicine at Yale School of Medicine and Yale-New Haven Hospital. Dr. Desir is a REMED co-founder and chair of its Scientific Advisory Board. REMED is advancing a Renalase agonist RT-1002 to IND for acute organ injury including acute pancreatitis (AP), followed by acute kidney injury (AKI). RT-1002 has first- and best-in-class potential as a therapeutic for inflammation and pain in acute pancreatitis and blunting progression to chronic pancreatic disease. REMED also has two pre-clinical Renalase antagonist programs, biological and small molecule therapeutics, in development for the treatment of various forms of cancer including melanoma, colon, and pancreatic cancers, as well as multiple myeloma. The ability to measure Renalase levels and treat gives REMED unique  precision medicine advantages and the potential for a standalone diagnostics. 
REMED has strong IP across its portfolio of Renalase therapeutics with patent life up to 2041 + 5 years Patent Life Extension (PTE) in the US



REMED Therapeutics

Org chart

Teams

Offices